Volume 30, Number 9—September 2024
Dispatch
Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023
Table
Antimicrobial | F95 MIC, mg/L | F96 MIC, mg/L | EUCAST interpretation | Molecular mechanism(s) of resistance |
---|---|---|---|---|
Penicillin |
>32 |
>32 |
R |
blaTEM-135 |
Cefixime | 1 | 1 | R | penA 60.001 (mosaic; A311V; T483S); mtrR, A39T; ponA, L421P; porB structure, porB1a |
Ceftriaxone | 0.25 | 0.25 | R | |
Cefotaxime |
0.5 |
0.5 |
R |
|
Ertapenem |
0.032 |
0.016 |
NA |
NA |
Azithromycin |
>256 |
>256 |
R (high-level) |
23S rRNA, A2059G; mtrR, A39T |
Tetracycline | 32 | 32 | R (high-level) | tetM; rpsJ, V57M; mtrR, A39T |
Doxycycline |
16 |
16 |
R |
|
Ciprofloxacin |
2 |
4 |
R |
gyrA, S91F and D95A; parC, S87R |
Spectinomycin |
16 |
16 |
S |
NA |
Gentamicin |
8 |
8 |
NA |
NA |
Rifampin |
0.125 |
0.064 |
NA |
NA |
*MIC testing done using ETEST (bioMérieux, https://www.biomerieux.com). EUCAST, European Committee on Antimicrobial Susceptibility testing; NA, not applicable because of a lack of breakpoints for interpretation; R, resistant; S, susceptible. |
1These authors contributed equally to this article.
Page created: July 12, 2024
Page updated: August 21, 2024
Page reviewed: August 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.